Armata Pharmaceuticals, Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Armata Pharmaceuticals, Inc. (ARMP) is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. The company offers a broad pipeline of natural and synthetic phage candidates, including lead products AP-PA02, an inhaled therapy for chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis and bronchiectasis patients; AP-SA02, an intravenous therapy for Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa pneumonia; with additional candidates targeting other pathogens. Founded in 2019 through the merger of AmpliPhi Biosciences Corporation (established 1989) and C3J Therapeutics, Inc., Armata Pharmaceuticals maintains headquarters in Marina del Rey, California, and conducts worldwide operations in the biotech and pharma sectors serving patients with chronic and acute infections. Recent developments include positive topline results from the Phase 1b/2a diSArm trial of AP-SA02 meeting all primary endpoints for safety, tolerability, and clinical response in May 2025; a $15 million secured credit agreement with Innoviva Strategic Opportunities LLC maturing in 2029 announced in August 2025 to advance lead programs; and $4.65 million in additional non-dilutive funding from the U.S. Department of Defense in early 2025 to support the diSArm trial, alongside plans for a Phase 3 pivotal study in 2026.
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8% – Still a Buy?
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Armata data support advancing AP-SA02 to Phase 3, says H.C. Wainwright
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?